Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07148505 · ClinicalTrials.gov registry record
A Study of Real-world Outcomes Among Patients Treated With Ribociclib
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 373
- Enrollment target
NCT07148505: Completed study, sponsored by Novartis Pharmaceuticals.
NCT07148505 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 373 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07148505 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 373 participants
- Enrollment target
Study Summary
The main aim of the study was to evaluate the real-world tolerability and safety of ribociclib as a first-line (1L) treatment among adults with hormone receptor-positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC). This study used data from the Flatiron Health Research Database (FHRD). The FHRD is a longitudinal database derived from electronic health records (EHRs) and other real-world data (RWD) sources from cancer care providers across the United States. The dataset generated for this study included de-identified patient-level data for eligible individuals between 1 January 2015 up to the data cutoff date, 30 November 2022.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 373 participants |
| Start Date | 2024-04-24 |
| Est. Completion | 2024-11-07 |
What the finished NCT07148505 record still lists
NCT07148505 is an observational study that tracks outcomes without assigning an intervention. The registered 373 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT07148505 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07148505 about?
NCT07148505 is a clinical study titled "A Study of Real-world Outcomes Among Patients Treated With Ribociclib". The main aim of the study was to evaluate the real-world tolerability and safety of ribociclib as a first-line (1L) treatment among adults with hormone receptor-positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC). This study used data from the Flati...
What is the current status of trial NCT07148505?
This trial is currently completed. The enrollment target is 373 participants. The study started on 2024-04-24. Estimated completion is 2024-11-07.
Who is sponsoring clinical trial NCT07148505?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07276750 · 373 participants · NA
Coaching and Leadership in Autism Support Settings
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- NCT05318105 · 372 participants · NA
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI